Abstract:Although TP53 co-mutation with KRAS have been proved to have predictive value for response to PD-1/L1 blockades, not all TP53 mutations are equal in this context. TP53 subtypes as independent factors to predict the response to PD-1/L1 blockade have not yet reported. We performed an integrated analysis on the multiple-dimensional data types including genomic and clinical data from cohorts of NSCLC public (240 from MSK database) and local databases (224 patient with PD-L1 IHC score, 1986 NSCLC with TMB data). Durable clinical beneﬁt (DCB) was deﬁned as partial response/stable disease that lasted more than 6 months. The presence of mutant TP53 was associated with longer median progression free survival (mPFS) in NSCLC taking PD-1/L1 blockade therapy compared with TP53 wild-type group in the MSK-cohort (4.3 vs2.6 months, P=0.0027, HR=0.6409, 95%CI, 0.49 to 0.88). TP53 frameshift seemed to predict longer mPFS (6.6 months, P=0.0159, HR= 0.41, 95%CI, 0.26 to 0.65) than TP53 wild-type, TP53 missense (mPFS=4.27 months, P=0.17) and TP53 nonsense status (mPFS=2.7 months, P=0.002).NSCLC with TP53 frameshift mutation had a 52.9% rate of DCB, which was higher than TP53 missense (34.4%) and nonsense (21.1%) group. Besides, in the MSK cohort, five of six patients with TP53 truncated mutation in proline-rich (PR) domain (residues 58--101) achieved DCB, and one patient achieved 5.5 months of PFS and did not progress. Fractions of PD-L1 low-positive (1% - 49%) and PD-L1 high-positive (≥50%) tumors between each TP53 mutation subtype and wild-type groups are analyzed based on local data. The TP53 mutation rate was significantly higher in NSCLC with PD-L1 score >50% (P=0.004). But NSCLC with TP53 frameshift showed lower fractions of PD-L1 high-positive (12.5%, 2/16) compared with TP53 missense group (27.5%, 33/120) and TP53 nonsense group (25.8%, 8/31). PD-L1 low-positive rate is also lower in TP53 frameshift group (25.0%, 4/16) than TP53 missense (30.8%, 37/120) and nonsense group (29.0%, 9/31). Among 1986 NSCLC patients with TMB data, each TP53 mutation subtype is associated with significantly higher TMB than TP53 wildtype, especially among NSCLC with TP53 truncated mutation in PR domain (median TMB= 9 mut/Mbs). But no significant difference was found between TP53 mutation subtypes in TMB. Our study demonstrated heterogeneity among TP53 mutations in predicting the response to PD-1/L1 blockade therapy. TP53 frameshift mutation may contribute to better PD-1/L1 blockade therapy response beyond PD-1/L1 IHC status. And the truncated TP53 mutation in PR domain may contribute to DCB.

P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients

Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

JCSE01.23 Specific TP53 Mutation Subtypes As Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC

P1.03-08 Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China

EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC

P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

P1.03-23 the Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

EP1.03-24 Clinicopathologic Characteristics and Survival Outcome in Chinese Patients with Non-Small Cell Lung Cancer and HGF Mutations

P1.03-10 the Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients

P1.03-26 Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

P1.02-048 Somatic Mutation Analysis of RB1 Gene in Chinese Non-Small Cell Lung Cancer Patients

P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients

P2.16-08 Clinical Characteristics and Outcomes of Patients with BRAF Mutated Non-Small Cell Lung Cancer

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations